Table 1 Patient background.

From: Determining the immune environment of cutaneous T-cell lymphoma lesions through the assessment of lesional blood drops

Pt

Age

(yr)

Sex

Disease

Stage

mSWAT

CD8/45RO

(%, PB)

CD8/45RO

(%, LB)

Tissue

CD8/45RO

CyTOF

RNA-seq

TCR repertoire

Treatment

1

83

M

MF

IB

44

10.4

11.2

45

   

Chemo + PUVA

2

68

M

MF

IB

49

0.18

0.5

45

   

Chemo

3

61

F

MF

IIIA

64

3.25

3.54

44

   

Chemo + PUVA

4

88

F

MF

IB

38

7.69

9.18

89

 

CD8/45RO

CD8/45RO

PUVA

5

71

F

MF

IB

102

3.12

4.03

19

â—‹

  

Chemo + PUVA

6

82

M

MF

IB

40

0.65

0.72

67

â—‹

  

Chemo

7

56

F

MF

IB

36

2.22

2.33

71

â—‹

  

Chemo + PUVA

8

70

M

MF

IIIA

138

0.34

0.26

13

   

Chemo + PUVA

9

78

F

MF

IB

22

1.71

3.81

135

â—‹

  

Chemo + PUVA

10

71

M

MF

IIB

109

0.76

0.97

23

â—‹

 

CD8/45RO

Chemo + PUVA

11

64

F

MF

IB

70

2.3

2.4

82

  

CD4/45RO

Chemo + PUVA

12

72

F

MF

IB

39

12.6

11.8

167

 

CD4/45RO

 

Chemo + PUVA

13

78

M

MF

IA

15

13

15

178

   

PUVA

14

72

M

MF

IB

22

1.5

1.9

154

  

CD8/45RO

Chemo + PUVA

15

45

F

MF

IA

14

1.88

2.3

   

CD8/45RO

Chemo + PUVA

16

67

M

MF

IIIA

94

1.16

1.81

  

CD4/45RO

 

Chemo

17

45

M

MF

IB

26

1.71

1.7

  

CD4/45RO

 

Chemo + PUVA

18

70

M

MF

IB

35

3.42

3.44

  

CD8/45RO

 

Chemo + PUVA

19

34

F

MF

IB

40

1.26

1.45

  

CD8/45RO

 

Chemo + PUVA

  1. All MF patients are CD4+ MF and underwent skin biopsies on admission treatment. MF mycosis fungoides, Chemo chemotherapy (bexarotene), PUVA psoralen and ultraviolet A.
Back to article page